Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2016, Article ID 4897515, 10 pages
http://dx.doi.org/10.1155/2016/4897515
Review Article

Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine

1Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35249-6832, USA
2Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA

Received 20 November 2015; Accepted 20 January 2016

Academic Editor: Robert Gardiner

Copyright © 2016 Caleb R. Dulaney et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2015,” CA: A Cancer Journal for Clinicians, vol. 65, no. 1, pp. 5–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. M. D. Krahn, J. E. Mahoney, M. H. Eckman, J. Trachtenberg, S. G. Pauker, and A. S. Detsky, “Screening for prostate cancer. A decision analytic view,” The Journal of the American Medical Association, vol. 272, no. 10, pp. 773–780, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. M. S. Cohen, R. S. Hanley, T. Kurteva et al., “Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis,” European Urology, vol. 54, no. 2, pp. 371–381, 2008. View at Publisher · View at Google Scholar
  4. J. C. Presti Jr., G. J. O'Dowd, M. C. Miller, R. Mattu, and R. W. Veltri, “Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study,” The Journal of Urology, vol. 169, no. 1, pp. 125–129, 2003. View at Google Scholar · View at Scopus
  5. F. M. E. Wagenlehner, E. Van Oostrum, P. Tenke et al., “Infective complications after prostate biopsy: outcome of the Global Prevalence study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study,” European Urology, vol. 63, no. 3, pp. 521–527, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. V. D'Amico, M. Schnall, R. Whittington et al., “Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease,” Urology, vol. 51, no. 3, pp. 449–454, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Tatli, K. J. Mortele, E. L. Breen, R. Bleday, and S. G. Silverman, “Local staging of rectal cancer using combined pelvic phased-array and endorectal coil MRI,” Journal of Magnetic Resonance Imaging, vol. 23, no. 4, pp. 534–540, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Sella, L. H. Schwartz, P. W. Swindle et al., “Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging,” Radiology, vol. 231, no. 2, pp. 379–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Turkbey, V. P. Shah, Y. Pang et al., “Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?” Radiology, vol. 258, no. 2, pp. 488–495, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Komai, N. Numao, S. Yoshida et al., “High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy,” The Journal of Urology, vol. 190, no. 3, pp. 867–873, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Volkin, B. Turkbey, A. N. Hoang et al., “Multiparametric Magnetic Resonance Imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers,” BJU International, vol. 114, no. 6, pp. E43–E49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Turkbey, H. Mani, V. Shah et al., “Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds,” Journal of Urology, vol. 186, no. 5, pp. 1818–1824, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. J. V. Hegde, R. V. Mulkern, L. P. Panych et al., “Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer,” Journal of Magnetic Resonance Imaging, vol. 37, no. 5, pp. 1035–1054, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. R. Engelbrecht, P. Puech, P. Colin, O. Akin, L. Lemaître, and A. Villers, “Multimodality magnetic resonance imaging of prostate cancer,” Journal of Endourology, vol. 24, no. 5, pp. 677–684, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Rais-Bahrami, M. M. Siddiqui, S. Vourganti et al., “Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies,” BJU International, vol. 115, no. 3, pp. 381–388, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. O. F. Donati, Y. Mazaheri, A. Afaq et al., “Prostate cancer aggressiveness: assessment with whole-lesion histogram analysis of the apparent diffusion coefficient,” Radiology, vol. 271, no. 1, pp. 143–152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Siddiqui, S. Rais-Bahrami, H. Truong et al., “Magnetic resonance imaging/ultrasound fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy,” European Urology, vol. 64, no. 5, pp. 713–719, 2013. View at Publisher · View at Google Scholar
  18. S. Rais-Bahrami, M. M. Siddiqui, B. Turkbey et al., “Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer,” The Journal of Urology, vol. 190, no. 5, pp. 1721–1727, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. J. K. Logan, S. Rais-Bahrami, B. Turkbey et al., “Current status of Magnetic Resonance Imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies,” BJU International, vol. 114, no. 5, pp. 641–652, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Beyersdorff, A. Winkel, B. Hamm, S. Lenk, S. A. Loening, and M. Taupitz, “MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results,” Radiology, vol. 234, no. 2, pp. 576–581, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. P. Lichy, A. G. Anastasiadis, P. Aschoff et al., “Morphologic, functional, and metabolic magnetic resonance imaging-guided prostate biopsy in a patient with prior negative transrectal ultrasound-guided biopsies and persistently elevated prostate-specific antigen levels,” Urology, vol. 69, no. 6, pp. 1208.e5–1208.e8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Engelhard, H. P. Hollenbach, B. Kiefer, A. Winkel, K. Goeb, and D. Engehausen, “Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device,” European Radiology, vol. 16, no. 6, pp. 1237–1243, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Hambrock, C. Hoeks, C. Hulsbergen-van de Kaa et al., “Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort,” European Urology, vol. 61, no. 1, pp. 177–184, 2012. View at Publisher · View at Google Scholar
  24. J. Haffner, L. Lemaitre, P. Puech et al., “Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection,” BJU International, vol. 108, no. 8, pp. E171–E178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. B. K. Park, J. W. Park, S. Y. Park et al., “Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy,” American Journal of Roentgenology, vol. 197, no. 5, pp. W876–W881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Puech, O. Rouvière, R. Renard-Penna et al., “Prostate cancer diagnosis: multiparametric mr-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy—prospective multicenter study,” Radiology, vol. 268, no. 2, pp. 461–469, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. G. A. Sonn, E. Chang, S. Natarajan et al., “Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen,” European Urology, vol. 65, no. 4, pp. 809–815, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. M. M. Siddiqui, S. Rais-Bahrami, B. Turkbey et al., “Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer,” The Journal of the American Medical Association, vol. 313, no. 4, pp. 390–397, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. J. J. Fütterer, A. Briganti, P. De Visschere et al., “Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature,” European Urology, vol. 68, no. 6, pp. 1045–1053, 2015. View at Publisher · View at Google Scholar
  30. L. Stamatakis, M. M. Siddiqui, J. W. Nix et al., “Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer,” Cancer, vol. 119, no. 18, pp. 3359–3366, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. N. B. Delongchamps, M. Peyromaure, A. Schull et al., “Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies,” Journal of Urology, vol. 189, no. 2, pp. 493–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Meng, A. B. Rosenkrantz, N. Mendhiratta et al., “Relationship between prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes,” European Urology, 2015. View at Publisher · View at Google Scholar
  33. A. A. Martinez, Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer, ClinicalTrials.gov, National Library of Medcine, Bethesda, Md, USA, 2000, https://clinicaltrials.gov/ct2/show/NCT00936390.
  34. J. M. Pawlowski, E. S. Yang, A. W. Malcolm, C. W. Coffey, and G. X. Ding, “Reduction of dose delivered to organs at risk in prostate cancer via image-guided radiation therapy,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 3, pp. 924–934, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. D. A. Kuban, S. L. Tucker, L. Dong et al., “Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 70, no. 1, pp. 67–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. W. D. Heemsbergen, A. Al-Mamgani, A. Slot, M. F. H. Dielwart, and J. V. Lebesque, “Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival,” Radiotherapy and Oncology, vol. 110, no. 1, pp. 104–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. A. L. Zietman, K. Bae, J. D. Slater et al., “Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College Of Radiology 95–09,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1106–1111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Beckendorf, S. Guerif, E. Le Prisé et al., “70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial,” International Journal of Radiation Oncology, Biology, Physics, vol. 80, no. 4, pp. 1056–1063, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. D. P. Dearnaley, G. Jovic, I. Syndikus et al., “Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial,” The Lancet Oncology, vol. 15, no. 4, pp. 464–473, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Kalbasi, J. Li, A. Berman et al., “Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer,” JAMA Oncology, vol. 1, no. 7, pp. 897–906, 2015. View at Publisher · View at Google Scholar
  41. P. J. Gray, J. J. Paly, B. Y. Yeap et al., “Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer,” Cancer, vol. 119, no. 9, pp. 1729–1735, 2013. View at Publisher · View at Google Scholar
  42. N. C. Sheets, G. H. Goldin, A.-M. Meyer et al., “Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer,” The Journal of the American Medical Association, vol. 307, no. 15, pp. 1611–1620, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. B. Yu, P. R. Soulos, J. Herrin et al., “Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity,” Journal of the National Cancer Institute, vol. 105, no. 1, pp. 25–32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Lukka, C. Hayter, J. A. Julian et al., “Randomized trial comparing two fractionation schedules for patients with localized prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6132–6138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. E. E. Yeoh, R. J. Botten, J. Butters, A. C. Di Matteo, R. H. Holloway, and J. Fowler, “Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 5, pp. 1271–1278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Dearnaley, I. Syndikus, G. Sumo et al., “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial,” The Lancet Oncology, vol. 13, no. 1, pp. 43–54, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. K. E. Hoffman, K. R. Voong, T. J. Pugh et al., “Risk of Late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial,” International Journal of Radiation Oncology Biology Physics, vol. 88, no. 5, pp. 1074–1084, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Arcangeli, L. Strigari, S. Gomellini et al., “Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 84, no. 5, pp. 1172–1178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Pollack, G. Walker, E. M. Horwitz et al., “Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer,” Journal of Clinical Oncology, vol. 31, no. 31, pp. 3860–3868, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Wilkins, H. Mossop, I. Syndikus et al., “Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localized prostate cancer: 2-year patient-reported outcomes of the randomized, non-inferiority, phase 3 CHHiP trial,” The Lancet Oncology, vol. 16, no. 16, pp. 1605–1616, 2015. View at Publisher · View at Google Scholar
  51. W. R. Lee, J. J. Dignam, M. Amin et al., “NRG oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer,” Journal of Clinical Oncology, vol. 34, supplement 2S, abstract 1, 2016, Proceedings of the Genitourinary Cancers Symposium. View at Google Scholar
  52. S. Aluwini, F. Pos, E. Schimmel et al., “Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial,” The Lancet Oncology, vol. 16, no. 3, pp. 274–283, 2015. View at Publisher · View at Google Scholar
  53. C. Catton, H. Lukka, M. Levine, and J. Julian, “A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer,” in ClinicalTrials.gov, National Library of Medicine (US), Bethesda, Md, USA, 2000, NLM identifier: NCT00304759, 2000, https://clinicaltrials.gov/ct2/show/NCT00304759. View at Google Scholar
  54. A. Widmark, Phase III Study of HYPOfractionated RadioTherapy of Intermediate Risk Localised Prostate Cancer, ControlledTrials.com, BioMed Central, London, UK, 2015, http://www.controlled-trials.com/ISRCTN45905321.
  55. P. Ostler, Prostate Advances in Comparative Evidence (PACE), ClinicalTrials.gov, National Library of Medcine, Bethesda, Md, USA, 2000, https://clinicaltrials.gov/ct2/show/NCT01584258.
  56. C. Vargas, “Study of hypo-fractionated proton radiation for low risk prostate cancer,” in ClinicalTrials.gov, National Library of Medicine (US), Bethesda, Md, USA, NLM identifier: NCT01230866, 2000, https://clinicaltrials.gov/ct2/show/NCT01230866.
  57. H. R. Lukka, Radiation Therapy in Treating Patients with Prostate Cancer, ClinicalTrials.gov, National Library of Medcine, Bethesda, Md, USA, 2000, https://clinicaltrials.gov/ct2/show/NCT01434290.
  58. N. Cellini, A. G. Morganti, G. C. Mattiucci et al., “Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning,” International Journal of Radiation Oncology Biology Physics, vol. 53, no. 3, pp. 595–599, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. W. Liu, S. Laitinen, S. Khan et al., “Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer,” Nature Medicine, vol. 15, no. 5, pp. 559–565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Pucar, H. Hricak, A. Shukla-Dave et al., “Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence,” International Journal of Radiation Oncology, Biology, Physics, vol. 69, no. 1, pp. 62–69, 2007. View at Publisher · View at Google Scholar
  61. V. Mouraviev, A. Villers, D. G. Bostwick, T. M. Wheeler, R. Montironi, and T. J. Polascik, “Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy,” BJU International, vol. 108, no. 7, pp. 1074–1085, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Fonteyne, G. Villeirs, B. Speleers et al., “Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 3, pp. 799–807, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. P. L. Nguyen, M.-H. Chen, Y. Zhang et al., “Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy,” Journal of Urology, vol. 188, no. 4, pp. 1151–1156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. W. J. Morris, S. Tyldesley, H. H. Pai et al., “ASCENDE-RT: a multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer,” Journal of Clinical Oncology, vol. 33, supplement 7, abstract 3, 2015. View at Google Scholar
  65. J. R. Sathya, I. R. Davis, J. A. Julian et al., “Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate,” Journal of Clinical Oncology, vol. 23, no. 6, pp. 1192–1199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. P. J. Hoskin, K. Motohashi, P. Bownes, L. Bryant, and P. Ostler, “High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial,” Radiotherapy and Oncology, vol. 84, no. 2, pp. 114–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. D. E. Spratt, X. Pei, J. Yamada, M. A. Kollmeier, B. Cox, and M. J. Zelefsky, “Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 85, no. 3, pp. 686–692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. J. B. Fiveash, “Pilot trial evaluating stereotactic body radiotherapy with integrated boost for clinically localized prostate cancer (RAD 1203),” in ClinicalTrials.gov, National Library of Medcine (US), Bethesda, Md, USA, NLM identifier: NCT01856855, 2000, https://clinicaltrials.gov/ct2/show/NCT01856855.
  69. M. R. Cooperberg, J. P. Simko, J. E. Cowan et al., “Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort,” Journal of Clinical Oncology, vol. 31, no. 11, pp. 1428–1434, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. J. T. Bishoff, S. J. Freedland, L. Gerber et al., “Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy,” The Journal of Urology, vol. 192, no. 2, pp. 409–414, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. M. R. Cooperberg, E. Davicioni, A. Crisan, R. B. Jenkins, M. Ghadessi, and R. J. Karnes, “Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort,” European Urology, vol. 67, no. 2, pp. 326–333, 2014. View at Publisher · View at Google Scholar · View at Scopus